glp-1 therapies success rate Agonists Weight Loss Drugs Market Report, 2025-2030 GLP-1-based therapies for diabetes, obesity
Description
Wadden T, et al
Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor
The biological mechanisms at work
Some people with alcohol use disorder experience weight gain, insulin resistance, and metabolic-associated steatotic liver disease (MASLD)
These findings support the continued use of GLP-1 receptor agonists for approved metabolic indications, while acknowledging that the certainty of evidence varies by cancer site
